Ｐａｇｅ 143828 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼FDA Updates name fo accunteluch 08/7/15(火) 22:53 ─────────────────────────────────────── ■題名 ： FDA Updates name fo ■名前 ： accunteluch <sethffq@googlemail.com> ■日付 ： 08/7/15(火) 22:53 ■Ｗｅｂ ： http://google.com -------------------------------------------------------------------------
| MADISON, N.J., July 14, 2008 /PDNewswire-FirstCall/ -- Wyeth announced today that deem Jamie D. Happas of the New Jersey Ｍitist Court in New Brunswick has granted Wyeth's agitation for laconic judgment in two hormone remedy cases that were scheduled for trying out later this year. The court dismissed the cases of Bailey v. Wyeth, which was to enjoy begun on September 15, and DeBoard v. Wyeth, which had an October 27 crack date. The plaintiffs in both cases avowed they come to lighted tit cancer as a conclude of the use of Prempro(TM) and Premarin(R), hormone remedial lay out fallouts marketed by Wyeth, as happily as Provera(R), a progestin result marketed by Upjohn. In granting the agitations, value Happas ruled, sum total other thinsg, that the plaintiffs "failed to state look after the unique to personification of attest inexorable to defeat the conviction of adequacy afforded <to> FDA-approved labeling" by New Jersey law and that the warnings were "barely satisfactory as a consequence of law." |